Approaches to hepatitis C treatment and cure using NS5A inhibitors

References

• LavanchyDThe global burden of hepatitis CLiver Int200929Suppl 1S74S81
   PubMed Web of Science ®Google Scholar
• AlterMJEpidemiology of hepatitis C virus infectionWorld J Gastroenterol200713172436244117552026
   PubMed Web of Science ®Google Scholar
• LehmannMMeyerMFMonazahianMTillmannHLMannsMPWedemeyerHHigh rate of spontaneous clearance of acute hepatitis C virus genotype 3 infectionJ Med Virol200473338739115170633
   PubMed Web of Science ®Google Scholar
• TongMJel-FarraNSReikesARCoRLClinical outcomes after transfusion-associated hepatitis CN Engl J Med199533222146314667739682
   PubMed Web of Science ®Google Scholar
• AlbertiAChemelloLBenvegnùLNatural history of hepatitis CJ Hepatol199931Suppl 1S17S24
   PubMed Web of Science ®Google Scholar
• LambersFAPrinsMThomasXMOSAIC (MSM Observational Study of Acute Infection with hepatitis C) study groupAlarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSMAIDS20112517F21F2721857492
   PubMed Web of Science ®Google Scholar
• Deuffic-BurbanSPoynardTSulkowskiMSWongJBEstimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United StatesJ Viral Hepat200714210711517244250
   PubMed Web of Science ®Google Scholar
• LohmannVHepatitis C virus RNA replicationCurr Top Microbiol Immunol201336916719823463201
   PubMed Web of Science ®Google Scholar
• MoorePSChangYWhy do viruses cause cancer? Highlights of the first century of human tumour virologyNat Rev Cancer2010101287888921102637
   PubMed Web of Science ®Google Scholar
• MoradpourDPeninFHepatitis C virus proteins: from structure to functionCurr Top Microbiol Immunol201336911314223463199
   PubMed Web of Science ®Google Scholar
• KimAISaabSTreatment of hepatitis CAm J Med2005118880881516084169
   PubMed Web of Science ®Google Scholar
• Wartelle-BladouCLe FolgocGBourlièreMLecomteLHepatitis C therapy in non-genotype 1 patients: the near futureJ Viral Hepat201219852553622762136
   PubMed Web of Science ®Google Scholar
• AlexopoulouAPapatheodoridisGVCurrent progress in the treatment of chronic hepatitis CWorld J Gastroenterol201218426060606923155334
   PubMed Web of Science ®Google Scholar
• ZeinNNRakelaJKrawittELReddyKRTominagaTPersingDHHepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study GroupAnn Intern Med199612586346398849147
   PubMed Web of Science ®Google Scholar
• WilsonGKStamatakiZIn vitro systems for the study of hepatitis C virus infectionInt J Hepatol2012201229259123056952
   PubMedGoogle Scholar
• MoradpourDPeninFRiceCMReplication of hepatitis C virusNat Rev Microbiol20075645346317487147
   PubMed Web of Science ®Google Scholar
• BarreiroPVispoEPovedaEFernández-MonteroJVSorianoVHepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the LiverClin Infect Dis201356456056623090932
   PubMed Web of Science ®Google Scholar
• AssisDNLimJKNew pharmacotherapy for hepatitis CClin Pharmacol Ther201292329430522850602
   PubMed Web of Science ®Google Scholar
• ShahNPierceTKowdleyKVReview of direct-acting antiviral agents for the treatment of chronic hepatitis CExpert Opin Investig Drugs201322911071121
   PubMed Web of Science ®Google Scholar
• KiserJJFlexnerCDirect-acting antiviral agents for hepatitis C virus infectionAnnu Rev Pharmacol Toxicol20135342744923140245
   PubMed Web of Science ®Google Scholar
• JesudianABGambarin-GelwanMJacobsonIMAdvances in the treatment of hepatitis C virus infectionGastroenterol Hepatol (NY)20128291101
   Google Scholar
• YangPLGaoMLinKLiuQVillarealVAAnti-HCV drugs in the pipelineCurr Opin Virol20111660761622440918
   PubMed Web of Science ®Google Scholar
• De ClercqEThe race for interferon-free HCV therapies: a snapshot by the spring of 2012Rev Med Virol201222639241122936636
   PubMed Web of Science ®Google Scholar
• FarnikHZeuzemSNew antiviral therapies in the management of HCV infectionAntivir Ther201217577178322626842
   PubMed Web of Science ®Google Scholar
• HuntDPockrosPWhat are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?Curr Gastroenterol Rep201315130323250703
   PubMedGoogle Scholar
• BeldaOTargett-AdamsPSmall molecule inhibitors of the hepatitis C virus-encoded NS5A proteinVirus Res20121701–211423009750
   PubMed Web of Science ®Google Scholar
• CordekDGBechtelJTMaynardATKazmierskiWMCameronCETargeting the NS5A protein of HCV: an emerging optionDrugs Future201136969171123378700
   PubMed Web of Science ®Google Scholar
• BartenschlagerRLohmannVPeninFThe molecular and structural basis of advanced antiviral therapy for hepatitis C virus infectionNat Rev Microbiol201311748249623748342
   PubMed Web of Science ®Google Scholar
• TellinghuisenTLMarcotrigianoJGorbalenyaAERiceCMThe NS5A protein of hepatitis C virus is a zinc metalloproteinJ Biol Chem200427947485764858715339921
   PubMed Web of Science ®Google Scholar
• BrassVBieckEMontserretRAn amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5AJ Biol Chem2002277108130813911744739
   PubMed Web of Science ®Google Scholar
• ShiSTPolyakSJTuHTaylorDRGretchDRLaiMMHepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteinsVirology2002292219821011878923
   PubMed Web of Science ®Google Scholar
• PeninFBrassVAppelNStructure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5AJ Biol Chem200427939408354084315247283
   PubMed Web of Science ®Google Scholar
• TellinghuisenTLMarcotrigianoJRiceCMStructure of the zinc-binding domain of an essential component of the hepatitis C virus replicaseNature2005435704037437915902263
   PubMed Web of Science ®Google Scholar
• LoveRABrodskyOHickeyMJWellsPACroninCNCrystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virusJ Virol20098394395440319244328
   PubMed Web of Science ®Google Scholar
• LimPJChatterjiUCordekDCorrelation between NS5A dimerization and hepatitis C virus replicationJ Biol Chem201228736308613087322801423
   PubMed Web of Science ®Google Scholar
• GuptaGQinHSongJIntrinsically unstructured domain 3 of hepatitis C Virus NS5A forms a “fuzzy complex” with VAPB-MSP domain which carries ALS-causing mutationsPLoS One201276e3926122720086
   PubMed Web of Science ®Google Scholar
• HanoulleXBadilloAVerdegemDPeninFLippensGThe domain 2 of the HCV NS5A protein is intrinsically unstructuredProtein Pept Lett20101781012101820450484
   PubMed Web of Science ®Google Scholar
• HughesMGriffinSHarrisMDomain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particlesJ Gen Virol200990Pt 61329133419264615
   PubMed Web of Science ®Google Scholar
• LiangYYeHKangCBYoonHSDomain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfoldedBiochemistry20074641115501155817880107
   PubMed Web of Science ®Google Scholar
• Ross-ThrieplandDAmakoYHarrisMThe C terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and releaseJ Gen Virol201394Pt 51009101823324467
   PubMed Web of Science ®Google Scholar
• AnsariIUStrikerRSubtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virusViruses20124123303331523342381
   PubMed Web of Science ®Google Scholar
• AppelNZayasMMillerSEssential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assemblyPLoS Pathog200843e100003518369481
   PubMed Web of Science ®Google Scholar
• KimSWelschCYiMLemonSMRegulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain IIIJ Virol201185136645665621525356
   PubMed Web of Science ®Google Scholar
• KanekoTTanjiYSatohSProduction of two phosphoproteins from the NS5A region of the hepatitis C viral genomeBiochem Biophys Res Commun199420513203267999043
   PubMed Web of Science ®Google Scholar
• KimJLeeDChoeJHepatitis C virus NS5A protein is phosphorylated by casein kinase IIBiochem Biophys Res Commun1999257377778110208859
   PubMed Web of Science ®Google Scholar
• ChenYCSuWCHuangJYPolo-like kinase 1 is involved in hepatitis C virus replication by hyperphosphorylating NS5AJ Virol201084167983799320534861
   PubMed Web of Science ®Google Scholar
• KatzeMGKwieciszewskiBGoodlettDRSer(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5AVirology2000278250151311118372
   PubMed Web of Science ®Google Scholar
• QuintavalleMSambuciniSDi PietroCDe FrancescoRNeddermannPThe alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylationJ Virol20068022113051131216943283
   PubMed Web of Science ®Google Scholar
• ReissSHarakCRomero-BreyIThe lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5APLoS Pathog201395e100335923675303
   PubMed Web of Science ®Google Scholar
• HuangYStaschkeKDe FrancescoRTanSLPhosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication?Virology200736411917400273
   PubMed Web of Science ®Google Scholar
• LemayKLTreadawayJAnguloITellinghuisenTLA hepatitis C virus NS5A phosphorylation site that regulates RNA replicationJ Virol20138721255126023115292
   PubMed Web of Science ®Google Scholar
• AppelNPietschmannTBartenschlagerRMutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domainJ Virol20057953187319415709040
   PubMed Web of Science ®Google Scholar
• EggerDWölkBGosertRExpression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complexJ Virol200276125974598412021330
   PubMed Web of Science ®Google Scholar
• GosertREggerDLohmannVIdentification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic repliconsJ Virol20037795487549212692249
   PubMed Web of Science ®Google Scholar
• ElazarMCheongKHLiuPGreenbergHBRiceCMGlennJSAmphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replicationJ Virol200377106055606112719597
   PubMed Web of Science ®Google Scholar
• HuangLHwangJSharmaSDHepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding proteinJ Biolog Chem2005280433641736428
   Web of Science ®Google Scholar
• HwangJHuangLCordekDGHepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteinsJ Virol20108424124801249120926572
   PubMed Web of Science ®Google Scholar
• Targett-AdamsPBoulantSMcLauchlanJVisualization of double-stranded RNA in cells supporting hepatitis C virus RNA replicationJ Virol20088252182219518094154
   PubMed Web of Science ®Google Scholar
• JiraskoVMontserretRLeeJYStructural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assemblyPLoS Pathog2010612e100123321187906
   PubMed Web of Science ®Google Scholar
• LaiCKJengKSMachidaKLaiMMAssociation of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5AJ Virol200882178838884818562541
   PubMed Web of Science ®Google Scholar
• LaiCKJengKSMachidaKChengYSLaiMMHepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiationVirology2008370229530917931678
   PubMed Web of Science ®Google Scholar
• SchogginsJWRiceCMInnate immune responses to hepatitis C virusCurr Top Microbiol Immunol201336921924223463203
   PubMed Web of Science ®Google Scholar
• IvanovAVBartoschBSmirnovaOAIsaguliantsMGKochetkovSNHCV and oxidative stress in the liverViruses20135243946923358390
   PubMed Web of Science ®Google Scholar
• GongGWarisGTanveerRSiddiquiAHuman hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa BProc Natl Acad Sci U S A200198179599960411481452
   PubMed Web of Science ®Google Scholar
• BishéBSyedGSiddiquiAPhosphoinositides in the hepatitis C virus life cycleViruses20124102340235823202467
   PubMed Web of Science ®Google Scholar
• ZhangLHongZLinWARF1 and GBF1 generate a PI4P-enriched environment supportive of hepatitis C virus replicationPLoS One201272e3213522359663
   PubMed Web of Science ®Google Scholar
• PloenDHafirassouMLHimmelsbachKTIP47 plays a crucial role in the life cycle of hepatitis C virusJ Hepatol20135861081108823354285
   PubMed Web of Science ®Google Scholar
• VogtDACamusGHerkerELipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A proteinPLoS Pathog201394e100330223593007
   PubMed Web of Science ®Google Scholar
• DahariHCotlerSJLaydenTJPerelsonASUnderstanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modelingJ Hepatol201358484084223246507
   PubMed Web of Science ®Google Scholar
• GuedjJDahariHRongLModeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeProc Natl Acad Sci U S A2013110103991399623431163
   PubMed Web of Science ®Google Scholar
• MacdonaldAHarrisMHepatitis C virus NS5A: tales of a promiscuous proteinJ Gen Virol200485Pt 92485250215302943
   PubMed Web of Science ®Google Scholar
• MasakiTSuzukiRMurakamiKInteraction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particlesJ Virol200882167964797618524832
   PubMed Web of Science ®Google Scholar
• MaYAnantpadmaMTimpeJMHepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteinsJ Virol2011851869720962101
   PubMed Web of Science ®Google Scholar
• GouklaniHBeyerCDrummerHGowansEJNetterHJHaqshenasGIdentification of specific regions in hepatitis C virus core, NS2 and NS5A that genetically interact with p7 and co-ordinate infectious virus productionJ Viral Hepat2013204e66e7123490391
   PubMed Web of Science ®Google Scholar
• QuezadaEMKaneCMThe stimulatory mechanism of hepatitis C virus NS5A protein on the NS5B catalyzed replication reaction in vitroOpen Biochem J20137111423407362
   PubMedGoogle Scholar
• QuezadaEMKaneCMThe hepatitis C virus NS5A stimulates NS5B during in vitro RNA synthesis in a template specific mannerOpen Biochem J20093394819590581
   PubMedGoogle Scholar
• FosterTLBelyaevaTStonehouseNJPearsonARHarrisMAll three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA bindingJ Virol201084189267927720592076
   PubMed Web of Science ®Google Scholar
• Targett-AdamsPGrahamEJMiddletonJSmall molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of actionJ Virol201185136353636821507963
   PubMed Web of Science ®Google Scholar
• LeeCMaHHangJQThe hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral proteinVirology20114141101821513964
   PubMed Web of Science ®Google Scholar
• CamusGHerkerEModiAADiacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid coreJ Biol Chem2013288149915992323420847
   PubMed Web of Science ®Google Scholar
• ReissSRebhanIBackesPRecruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartmentCell Host Microbe201191324521238945
   PubMed Web of Science ®Google Scholar
• CarvalhoFACarneiroFAMartinsICDengue virus capsid protein binding to hepatic lipid droplets (LD) is potassium ion dependent and is mediated by LD surface proteinsJ Virol20128642096210822130547
   PubMed Web of Science ®Google Scholar
• SamsaMMMondotteJAIglesiasNGDengue virus capsid protein usurps lipid droplets for viral particle formationPLoS Pathog2009510e100063219851456
   PubMed Web of Science ®Google Scholar
• LemmJAO’BoyleD2ndLiuMIdentification of hepatitis C virus NS5A inhibitorsJ Virol201084148249119812153
   PubMed Web of Science ®Google Scholar
• LemmJALeetJEO’BoyleDRDiscovery of potent hepatitis C virus NS5A inhibitors with dimeric structuresAntimicrob Agents Chemother20115583795380221576451
   PubMed Web of Science ®Google Scholar
• GaoMNettlesREBelemaMChemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature201046572949610020410884
   PubMed Web of Science ®Google Scholar
• ConteIGiulianoCErcolaniCSynthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell cultureBioorg Med Chem Lett20091961779178319216075
   PubMed Web of Science ®Google Scholar
• BarnesMDennisonHMatthewsNSpencerKinventorsArrow Therapeutics Ltd, assigneeMorpholinylanilinoquinazoline derivatives for use as antiviral agents US patent US 20080311076A1
   Google Scholar
• BiancoAReghellinVDonniciLMetabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activityPLoS Pathog201283e100257622412376
   PubMed Web of Science ®Google Scholar
• LimYSHwangSBHepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagationJ Biol Chem201128613112901129821297162
   PubMed Web of Science ®Google Scholar
• AmblardFZhangHZhouLSynthesis and evaluation of non-dimeric HCV NS5A inhibitorsBioorg Med Chem Lett20132372031203423466233
   PubMed Web of Science ®Google Scholar
• ZhangHZhouLAmblardFSynthesis and evaluation of novel potent HCV NS5A inhibitorsBioorg Med Chem Lett201222144864486822704887
   PubMed Web of Science ®Google Scholar
• ShiJZhouLAmblardFSynthesis and biological evaluation of new potent and selective HCV NS5A inhibitorsBioorg Med Chem Lett201222103488349122507961
   PubMed Web of Science ®Google Scholar
• ChangWMosleyRTBansalSInhibition of hepatitis C virus NS5A by fluoro-olefin based γ-turn mimeticsBioorg Med Chem Lett20122282938294222425564
   PubMed Web of Science ®Google Scholar
• AghemoAColomboMSelection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virusGastroenterology2013145124724923726875
   PubMedGoogle Scholar
• FridellRAQiuDWangCValeraLGaoMResistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon systemAntimicrob Agents Chemother20105493641365020585111
   PubMed Web of Science ®Google Scholar
• FridellRAWangCSunJHGenotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlationsHepatology20115461924193521809362
   PubMed Web of Science ®Google Scholar
• O’Boyle IiDRSunJHNowerPTCharacterizations of HCV NS5A replication complex inhibitorsVirology20134441–234335423896639
   PubMed Web of Science ®Google Scholar
• NettlesREGaoMBifanoMMultiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1Hepatology20115461956196521837752
   PubMed Web of Science ®Google Scholar
• PawlotskyJMNS5A inhibitors in the treatment of hepatitis CJ Hepatol201359237538223567084
   PubMed Web of Science ®Google Scholar
• LokASGardinerDFLawitzEPreliminary study of two antiviral agents for hepatitis C genotype 1N Engl J Med2012366321622422256805
   PubMed Web of Science ®Google Scholar
• EversonGTSimsKDRodriguez-TorresMInterim analysis of an interferon (IFN)- and ribavirin (RBV))-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BSM-791325 in treatment-naive, hepatitis C virus genotype 1-infected patientsJ Hepatol201358Suppl 1S573 abstract
   Web of Science ®Google Scholar
• WongKAWorthAMartinRCharacterization of hepatitis C virus resistance from a multiple dose clinical trial of the novel NS5A inhibitor GS-5885Antimicrob Agents Chemother Epub7222013
   Web of Science ®Google Scholar
• LawitzEJGruenerDHillJMA phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis CJ Hepatol2012571243122314425
   PubMed Web of Science ®Google Scholar
• GaneEHylandRDingXELECTRON: 100% suppression of viral load through 4 weeks’ post-treatment for sofosbuvir ledipasvir (gs-5885) ribavirin for 12 weeks in treatment-naïve and -experienced hepatitis C virus GT 1 PatientsPresented at the 20th Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2013Atlanta, GA
   Google Scholar
• Gilead SciencesGilead reports interim data from Phase 2 LONESTAR study [press release]Foster City, CAGilead Sciences2013 [May 2]. Available from: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1814329&highlight#sthash.eUDZEi5S.dpuf2013Accessed October 2, 2013
   Google Scholar
• MarcellinPMannsMPJanczewskaE12 week response-guided treatment with the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, plus pegylated interferon/ribavirin in treatment naive genotype 1 hepatitis C infected patientsAbstract presented at the 48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013Amsterdam, The Netherlands
   Google Scholar
• EversonGTdi BisceglieAMVierlingJMCombination of the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, and pegylated interferon plus ribavirin in treatment experienced patients with genotype 1 hepatitis C infectionAbstract presented at the 48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013Amsterdam, The Netherlands
   Google Scholar
• ThompsonAHanSShiffmanMLGS-5885 GS-9451 Peginterferon and ribavirin (PR) for six or twelve weeks achieves high SVR12 rates in treatment -naïve genotype a IL28B CC patientsAbstract presented at the 48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013Amsterdam, The Netherlands
   Google Scholar
• Gilead SciencesGilead announces update on Phase 3 study of oral fixed-dose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients [press release]Foster City, CAGilead Sciences2013 [March 26]. Available from: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1800517&highlight#sthash.9dxD7UZn.dpuf2013Accessed October 2, 2013
   Google Scholar
• KowdleyKVLawitzEPoordadFPhase 2b trial of interferon-free therapy for hepatitis C virus genotype 1N Engl J Med201437022223224428468
   PubMed Web of Science ®Google Scholar
• VinceBHillJMLawitzEJA randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4J Hepatol Epub2014113
   Web of Science ®Google Scholar
• LahserFLiuRBystolKA combination containing MK5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV repliconPresented at the 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9–13, 2012Boston, MA
   Google Scholar
• GaneEFosterGRClanciaraJAntiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patientsAbstract presented at the 45th Annual Meeting of the European Association for the Study of the LiverApril 14–18, 2010Vienna, Austria
   Google Scholar
• SpreenWWilfretDBechtelJGSK2336805 HCV NS5A inhibitor demonstrates potent antiviral activity in chronic hepatitis C (CHC) genotype 1 infection: Results from a first time in human (FTIH) single and repeat dose studyPresented at the 62nd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 6–9, 2011San Francisco, CA
   Google Scholar
• Vertex Pharmaceuticals IncorporatedVertex enters agreement with GlaxoSmithKline for Phase 2 all-oral study of VX-135 and GSK2336805 for the treatment of hepatitis C [press release]Cambridge, MAVertex Pharmaceuticals Incorporated2012 [Nov 1]. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=7177772013Accessed November 20, 2013
   Google Scholar
• LalezariJFarrellGShahPPPI-668, a potent new pan-genotypic HCV NS5A inhibitor: Phase 1 efficacy and safetyPresented at the 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9–13, 2012Boston, MA
   Google Scholar
• GermanPPangPYangCHealthy volunteer first-in-human evaluation of GS-5816, a novel second generation broad-genotypic NS5A inhibitor with potential for once-daily dosingAbstract presented at the 48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013Amsterdam, The Netherlands
   Google Scholar
• ChengGYuMPengBGS-5816, a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrierAbstract presented at the 48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013Amsterdam, The Netherlands
   Google Scholar
• Gilead SciencesPhase 2 Study of SOF+GS-5816 in treatment naive subjects with chronic HCV Available from: http://clinicaltrials.gov/ct2/show/NCT1858766. NLM identifier: NCT1858766Accessed October 2, 2013
   Google Scholar
• VinceBLawitzESearleSNovel NS5A inhibitor ACH-2928 Phase I results in HCV GT-1 patientsAbstract presented at the 47th Annual Meeting of the European Association for the Study of the LiverApril 18–22, 2012Barcelona, Spain
   Google Scholar
• Garcia-RiveraJChatterjiUGallayPCyclophilin inhibitor alisporivir (ALV) combinations with direct acting antivirals reveal strong synergistic anti-HCV effectsAbstract presented at the 48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013Amsterdam, the Netherlands
   Google Scholar
• LalezariJAgarwalKDusheikoGDose-ranging trial of PPI-461, a potent new pan-genotypic HCV NS5A inhibitor, in patients with HCV genotype-1 infectionAbstract presented at the 62nd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 5–9, 2011San Francisco, CA
   Google Scholar
• DumasELawalAMenonRPharmacokinetics, safety and tolerability of the HCV NS5a inhibitor ABT-267 following single and multiple doses in healthy adult volunteersAbstract presented at the 46th Annual Meeting of the European Association for the Study of the LiverMarch 30–April 3, 2011Berlin, Germany
   Google Scholar
• HuiJRobargeLRobisonHKocinskyHSDeshpandeMNo clinically significant pharmacokinetic interaction between sovaprevir and ACH-3102 in healthy volunteersAbstract presented at the 48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013Amsterdam, The Netherlands
   Google Scholar
• Bristol-Myers SquibbA phase 3 study in combination with BMS-790052 and BMS-650032 in Japanese hepatitis C virus (HCV) patients Available from: http://clinicaltrials.gov/ct2/show/NCT1497834. NLM identifier: NCT1497834Accessed October 10, 2013
   Google Scholar
• Gilead SciencesSafety and efficacy of sofosbuvir/GS-5885 fixed-dose combination ± ribavirin for the treatment of HCV (ION-2) Available from: http://clinicaltrials.gov/ct2/show/NCT1768286. NLM identifier: NCT1768286Accessed October 2, 2013
   Google Scholar
• MayersDVinceBHillJIDX719, HCV NS5A inhibitor, demonstrates pan-genotypic activity after three days of monotherapy in genotype 1, 2, 3 or 4 HCV-infected subjectsAbstract presented at the 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9–13, 2012Boston, MA
   Google Scholar
• ZhouXJVinceBHillJPharmacokinetics and pharmacodynamics of IDX719, a pan-genotypic HCV NS5A inhibitor in genotype 1, 2, 3 or 4 HCV-infected subjectsAbstract presented at the Asian Pacific Association for the Study of the LiverJune 6–10, 2013Singapore
   Google Scholar
• MerckSafety, Pharmacokinetics and pharmacodynamics of MK-8742 in hepatitis C infected males (MK-8742–8002 AM1) Available from: http://clinicaltrials.gov/ct2/show/NCT1532973. NLM identifier: NCT1532973Accessed October 10, 2013
   Google Scholar
• Abbott LaboratoriesAbbott presents promising Phase 2b interferon-free hepatitis C results at 2012 liver meeting® [press release]Abbott Park, ILAbbott Laboratories2012 [November 10]. Available from: http://www.abbott.com/news-media/press-releases/abbott-presents-promising-phase-2b-interferonfree-hepatitis-c-results-at-2012-liver-meeting.htmAccessed June 27, 2013
   Google Scholar
• clinical trialfacts.com [homepage on the Internet]Effect of omeprazole and ritonavir on GSK2336805 pharmacokinetics in healthy adultsClinicalTrialfacts.com2011 [updated October 1, 2013]. Available from: http://www.clinicaltrialfacts.com/hepatitis-c-chronic/effect-of-omeprazole-and-ritonavir-on-gs-115217/summaryAccessed October 13, 2013
   Google Scholar
• investorshub.advfn.com [homepage on the Internet]Post 94863Investors Hub2010 Available from: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49610323Accessed October 13, 2013
   Google Scholar
• bms.com [homepage on the Internet]Pipeline asset update for daclatasvir (DCV; BMS-790052)Bristol-Myers Squibb2012 [cited July 15, 2013]. Available from: http://www.bms.com/research/investigational/hepatitis/Pages/DCV-BMS-790052.aspxAccessed October 13, 2013
   Google Scholar